BTHE Stock - Boston Therapeutics, Inc.
Unlock GoAI Insights for BTHE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|
| Revenue | $9,336 | $16,329 | $31,723 | $29,356 | $98,878 |
| Gross Profit | $-22,705 | $-10,679 | $-35,410 | $29,356 | $4,731 |
| Gross Margin | -243.2% | -65.4% | -111.6% | 100.0% | 4.8% |
| Operating Income | $-785,934 | $-3,493,235 | $-2,033,409 | $-1,265,656 | $-1,263,954 |
| Net Income | $-907,883 | $-3,694,079 | $-3,601,217 | $-1,584,873 | $-3,737,524 |
| Net Margin | -9724.5% | -22622.8% | -11352.1% | -5398.8% | -3779.9% |
| EPS | $-0.01 | $-0.04 | $-0.04 | $-0.03 | $-0.09 |
Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.
Visit WebsiteEarnings History & Surprises
BTHEEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2021 | Oct 4, 2021 | — | $-2.70 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.02 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.00 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.02 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.00 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.00 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.01 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.01 | — | — |
Q3 2018 | Sep 30, 2018 | — | $0.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.00 | — | — |
Q1 2018 | Mar 27, 2018 | — | $-0.03 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.00 | — | — |
Q4 2017 | Nov 13, 2017 | — | $-0.02 | — | — |
Q3 2017 | Aug 11, 2017 | — | $0.00 | — | — |
Q2 2017 | May 11, 2017 | — | $-0.01 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.04 | — | — |
Latest News
Frequently Asked Questions about BTHE
What is BTHE's current stock price?
What is the analyst price target for BTHE?
What sector is Boston Therapeutics, Inc. in?
What is BTHE's market cap?
Does BTHE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BTHE for comparison